Skip to main content
. 2025 Apr 1;23(2):e4112. doi: 10.30498/ijb.2025.516588.4112

Table 3.

Univariate risk analysis of features in the nivolumab efficacy deep learning model and survival time.

miRNA coef HR HR lower 95% HR upper 95% p
hsa-let-7c -0.1176 0.8891 0.8195 0.9646 *0.0047
hsa-let-7g -0.1714 0.8425 0.7206 0.9851 *0.0317
hsa-mir-146a -0.0852 0.9184 0.8437 0.9997 *0.0491
hsa-mir-22 0.1955 1.2159 1.0295 1.4361 *0.0213
hsa-mir-23a 0.1695 1.1847 1.0204 1.3754 *0.0261
hsa-mir-30b -0.1295 0.8786 0.7992 0.9658 *0.0074
hsa-mir-30e -0.1731 0.8411 0.7140 0.9907 *0.0383